Intraneuronal Signaling & Neurobiological Pathways

Signal Transduction — General Themes

  • Definition: conversion of extracellular stimuli (ligands) into intracellular biochemical events that alter neuronal function.

  • Canonical information flow

    • Ligand → Receptor → Adaptor proteins → Intracellular signaling pathway(s) → Effector proteins (often via protein kinases) → Acute physiologic change ± gene-expression change.

  • Core purposes

    • Amplification\text{Amplification}: picomolar ligands → nanomolar intracellular messengers.

    • Specificity\text{Specificity}: parallel, compartmentalized pathways keep “channels of information” separate until integration is required.

    • Temporal/Spatial coding\text{Temporal/Spatial coding}: pathways differ in onset (milliseconds ⇆ hours) and localization (synapse, soma, nucleus), letting neurons filter rare vs. repetitive inputs.

Major Plasma-Membrane Receptor Types

  • Ligand-Gated Ion Channels (LGICs)

    • Fast (milliseconds) “first messengers” for glutamate, γ\gamma-aminobutyric acid (GABA), nicotinic ACh, 5-HT3, etc.

    • Example: Nicotinic ACh receptor

    • Pentamer; two ACh sites; pore opens when both are occupied → Na+Na^+ influx.

    • Ca2+Ca^{2+}-permeable LGICs also initiate downstream Ca^2+-dependent cascades.

  • G-Protein–Coupled Receptors (GPCRs)

    • 7-TM super-family (>700 genes); primary receptors for monoamines, peptides, odorants, light (rhodopsin).

    • Activate heterotrimeric G proteins → second-messenger production; produce “slow” synaptic transmission.

  • Receptor Tyrosine Kinases (RTKs)

    • Dimerize on neurotrophin/chemokine binding (e.g., TrkA/B for NGF/BDNF) → intrinsic/cytoplasmic tyrosine-kinase cascades.

GPCR Signaling Mechanics

  • Basal state: GαβγG_{\alpha\beta\gamma} + GDP.

  • Agonist-bound receptor → GDP release → GTPGTP binding → G<em>αG<em>{\alpha} + G</em>βγG</em>{\beta\gamma} dissociate and act on effectors.

  • Termination: intrinsic GαGTPaseG_{\alpha\text{GTPase}} hydrolyzes GTP→GDPGTP \to GDP; reassociation to trimer.

  • RGS proteins (>20 isoforms) accelerate GTPase activity (except for G$_s$ class).

Four principal heterotrimeric G proteins

G class

Effector system

GsG_s

Stimulates adenylate cyclase → ↑ cAMP

Gi/oG_i/o

Inhibits adenylate cyclase; βγ\beta\gamma subunits open GIRK or close Ca2+Ca^{2+} channels

Gq/11G_q/11

Activates PLCβ → DAG + IP$_3$

G12/13G_{12/13}

Rho/Rac pathways (not detailed)

Cyclic AMP Pathway (Gs / Gi)

  • G<em>sG<em>s-coupled receptors (β-adrenergic, D$1$, some 5-HT) stimulate adenylate cyclase → ATP→ACcAMPATP \xrightarrow{AC} cAMP.

  • G<em>iG<em>i-coupled receptors (α$2$-adrenergic, D$2$, 5-HT${1A}$) inhibit the same enzyme.

  • Main effector: Protein Kinase A (PKA)

    • Basal tetramer R<em>2C</em>2R<em>2C</em>2; cAMP binds R → R dissociates → C subunits phosphorylate ≈\approx hundreds of substrates (ion channels, synaptic vesicle proteins, metabolic enzymes, transcription factors).

    • Key transcription target: CREB; binds DNA CRE sites when Ser-133 is P\text{P} by PKA → gene programs for survival, long-term memory.

  • Signal termination

    • Phosphodiesterases (PDEs) convert cAMP→AMPcAMP \to AMP.

    • Non-selective blockade by caffeine; isoform-specific inhibitors (e.g., rolipram = PDE-4, PDE10A inhibitors—antipsychotic potential).

Phosphatidylinositol (PI) Pathway (Gq)

  • G<em>qG<em>q → PLCβ cleaves PIP$2$ (membrane lipid) →

    • IP$3$ (water-soluble) diffuses to ER → binds IP$3$ receptor → massive Ca2+Ca^{2+} release.

    • DAG (membrane-anchored) activates Protein Kinase C (PKC); some PKC isoforms also need Ca2+Ca^{2+}.

  • Ca2+Ca^{2+} downstream actions

    • Immediate: neurotransmitter release, opening of Ca2+Ca^{2+}-activated K$^+$ or Cl$^−$ channels.

    • Delayed: via calmodulin → CaM-kinases (e.g., CaMKII) → gene transcription, metabolism.

  • Termination: IP$_3$ dephosphorylated to inositol; DAG degraded/recycled; Ca2+Ca^{2+} pumped out/into ER.

  • Lithium inhibits inositol phosphatases → “phosphatidylinositol rundown” hypothesis for mood stabilization; also inhibits certain AC isoforms & GSK-3.

Additional Second-Messenger Systems

  • cGMP / Nitric Oxide (NO)

    • Ca2+Ca^{2+}-calmodulin activates NOS → L-Arg→NO\text{L-Arg} \to NO.

    • NO diffuses locally → activates soluble guanylate cyclase → GTP→cGMPGTP \to cGMP.

    • Effector: Protein Kinase G (PKG); terminated by PDEs (e.g., sildenafil inhibits PDE-5 in penile smooth muscle).

  • Arachidonic Acid (AA) Pathway

    • GPCR-driven or Ca2+Ca^{2+}-driven PLA$2$ cleaves PIP$2$ → AA.

    • AA → COX → prostaglandins/thromboxanes OR LOX → leukotrienes.

    • Lipophilic metabolites modulate ion channels, AC/GC, & can exit cell to stimulate their own GPCRs.

    • COX-2 inhibitors investigated for schizophrenia/depression (anti-inflammatory rationale).

Direct Modulation of Ion Channels by G Proteins

  • GβγG_{\beta\gamma} from Gi/o-coupled receptors

    • Opens GIRK (inward-rectifier K$^+$) → hyperpolarization.

    • Inhibits presynaptic voltage-gated Ca2+Ca^{2+} channels → ↓ neurotransmitter release.

  • PIP$2$ dependency: PLC-driven PIP$2$ depletion can dampen channels requiring PIP$_2$.

Regulation of GPCR Function

  • GTPase acceleration: RGS proteins; knockout of RGS2 → ↑ anxiety; ↓ RGS9 in schizophrenia.

  • Desensitization / Internalization

    • GRKs phosphorylate agonist-occupied receptor.

    • Arrestin binds phosphorylated receptor → blocks G protein coupling + links to clathrin-mediated endocytosis.

    • Fates: recycling or lysosomal degradation; internal endosomal GPCRs can signal (location bias).

Protein Phosphatases & Their Modulators

  • Major brain phosphatases: PP1, PP2A, PP2B (calcineurin), PP2C.

  • Calcineurin = Ca2+/Ca^{2+}/calmodulin-activated; inhibited by tacrolimus.

  • PP Inhibitors

    • Inhibitor-1/2: phosphorylation by PKA enhances inhibition of PP1.

    • DARPP-32 (32 kDa dopamine- and cAMP-regulated phosphoprotein)

    • Phosphorylated by PKA → potent PP1 inhibitor.

    • Dephosphorylated by calcineurin; integrates D1 (cAMP) and Ca2+Ca^{2+} signals; implicated in drug abuse.

Tyrosine-Kinase Signaling Cascades

Neurotrophin → Trk Receptors

  • Ligand (NGF, BDNF) binds two Trk monomers → dimerization → autophosphorylation of cytoplasmic tyrosines.

  • Phosphotyrosines recruit Grb2 (SH2 domain) → SOS (GEF) → small G protein Ras-GTP.

MAPK (ERK) Cascade

  • Activated Ras → MAP3K Raf → MAP2K MEK → MAPK ERK.

  • ERK targets: transcription factors (CREB, c-Myc), cytosolic proteins; links GPCR-PKC input and growth-factor input.

  • Stress-activated JNK & p38 cascades: alternative MAPK branches.

PI3K / Akt Pathway

  • Ras/RTK recruitment of PI3K: PIP<em>2→PI3KPIP</em>3PIP<em>2 \xrightarrow{PI3K} PIP</em>3.

  • PIP$_3$ docks PDK1 + Akt; Akt phosphorylated, released.

    • Activates NF-κB via IκB kinase.

    • Inhibits GSK-3 (therapeutic lithium target).

    • Promotes cell survival, growth.

mTOR — Protein-Synthesis Hub

  • Downstream of PI3K–Akt, BDNF, GPCRs, and Ca2+Ca^{2+} influx.

  • Phosphorylates

    • 4E-BP → frees eIF4E for translation initiation at mRNA 5′ cap.

    • S6K → activates eEF2K → elongation facilitation.

  • Pathologic up-regulation: fragile X, autism, tuberous sclerosis.

  • Rapid antidepressant (ketamine) ⇒ ↑ mTOR-dependent spine formation in PFC.

Wnt / β-Catenin / GSK-3 Signaling

  • No Wnt: Axin + APC + GSK-3-active → phosphorylate β-catenin → ubiquitin degradation.

  • Wnt + Frizzled → Dishevelled disrupts complex → GSK-3 off → β-catenin accumulates → nucleus → gene transcription.

  • GSK-3 isoforms ($\alpha,\beta$) constitutively active; inhibited by insulin-Akt, mTOR feedback, PKC, PKA, lithium.

  • Psychiatric interest: GSK-3 inhibition as mood stabilizer; cross-talk node across signaling systems.

Synaptic Plasticity & Long-Term Potentiation (LTP)

  • Model synapse: CA1 hippocampal glutamatergic.

  • Early LTP (minutes→hours)

    • Glutamate → AMPA → Na+Na^+ depolarization.

    • Sufficient depolarization removes Mg$^{2+}$ block from NMDA → Ca2+Ca^{2+} influx.

    • Ca2+Ca^{2+}/calmodulin → CaMKII & PKC:

    • Phosphorylate AMPA (↑ conductance).

    • Traffic additional AMPA receptors from perisynaptic pools.

  • Late LTP (hours→days)

    • Requires new protein synthesis (local dendritic + somatic).

    • mTOR-regulated translation of receptors & scaffolds remodels spine morphology.

  • Additional modulators: GPCRs, neurotrophins (BDNF), NO retrograde signaling.

Signaling Complexes & Scaffolds

  • Purposes: speed, compartmentalization, specificity.

  • Domains & examples

    • SH2 / SH3: bind phosphotyrosine motifs (Grb2, PLCγ).

    • PDZ: assembles postsynaptic density (PSD-95, GRIP, SAP102) anchoring AMPA/NMDA, GPCRs, nNOS.

    • AKAPs: tether PKA near substrates (e.g., L-type Ca2+Ca^{2+} channels).

  • Result: nanodomains with dedicated “private” second-messenger pools.

Functional Selectivity (Biased Agonism)

  • A ligand can differentially activate available receptor pathways (G protein vs arrestin vs ERK etc.).

  • μ-Opioid receptor case

    • Full G-protein bias → strong analgesia, reduced arrestin recruitment → less tolerance in β-arrestin-2 knockout mice.

    • Dependence still develops → balanced vs biased agonist choice remains open.

  • Mechanisms

    • Ligand-specific receptor conformations.

    • Differential coupling to diverse G proteins, scaffolds, receptor dimerization.

    • Intracellular vs plasma-membrane receptor pools (location bias).

Remote Control of Signaling — Chemogenetics & Optogenetics

  • Opto-XRs: rhodopsin backbone + intracellular loops of β-adrenergic / 5-HT → light-driven GPCR signaling (millisecond precision).

  • DREADDs / RASSLs: mutated muscarinic, κ-opioid, etc. responding only to inert synthetic ligand (e.g., clozapine-N-oxide) → non-invasive, minute-scale control of G$s$, G$i$, G$_q$ pathways.

  • Ongoing engineering: enzyme-based actuators, drug-induced dimerization modules → prospective therapeutics.

Clinical & Research Implications / Future Directions

  • Intraneuronal signaling elucidation already informs

    • PDE-5 inhibitors (erectile dysfunction), PDE-4 (depression), PDE-10A (psychosis).

    • mTOR-based fast antidepressants (ketamine/esketamine).

    • COX-2 inhibitors as adjuncts in schizophrenia/MDD.

    • Biased agonists in pain (MOR) and other GPCR targets.

  • Anticipated advances

    • Intracellular target-based diagnostics (phospho-proteomics).

    • Drugs acting at signaling nodes (GSK-3, mTOR, RGS, β-arrestin interaction sites).

    • Precision chemogenetic therapies.

Key Numerical / Biochemical Details

  • G proteins ≈ 2%2\% of human genes encode GPCRs.

  • PDE10A highly expressed in striatum; inhibitors show antipsychotic-like effects in preclinical models.

  • mTOR translation control

    • Initiation: phosphorylation of 4E-BP at Ser-65, Thr-70, Ser-83 (relieves eIF4E sequestration).

    • Elongation: S6K phosphorylates eEF2K at Ser-366 → ↓ eEF2 phosphorylation → ↑ elongation rate.

  • LTP onset: postsynaptic [Ca2+]i[Ca^{2+}]_{i} can rise from ∼100 nM\sim100\,\text{nM} resting to >1\,\mu\text{M} within ms.

Ethical / Philosophical Notes

  • Intracellular pathway modulation offers specificity but raises concerns about unforeseen off-target network effects due to pathway redundancy.

  • Chemogenetic human therapies would require deliberation over genetic manipulation acceptability, long-term control, and equity of access.